Lemaitre Dan 4

What Happened
Dan Lemaitre, a director of Globus Medical (GMED), was granted a derivative award for 15,000 shares on January 21, 2026. The filing reports an acquisition price of $0.00 (total reported value $0), indicating a grant/award rather than a purchase or sale. The Form 4 covering this transaction was filed on January 23, 2026.

Key Details

• Transaction date: January 21, 2026 (Period of Report: 2026-01-21); Form 4 filed: January 23, 2026 (Accession: 0001193125-26-021222).
• Transaction type/code: Grant / Award (derivative) — Code A.
• Amount: 15,000 derivative shares reported at $0.00. Reported total value: $0.
• Vesting: Per footnote F1, the award was granted Jan 21, 2026 and will vest on January 1, 2027.
• Shares owned after transaction: Not specified in the publicly filed Form 4.
• Timeliness: Filing appears timely (filed two days after the reported transaction); no late filing flag noted.

Context
This is an award/grant (derivative) rather than an open-market buy or sale. The $0.00 price often indicates a stock award (e.g., restricted stock units or similar) that will convert to ordinary shares only after vesting conditions are met; it is not an immediate cash exercise. Such awards are typically part of compensation or director pay and do not, by themselves, indicate a buy/sell sentiment.